echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Favorites . . . In the second half of the pharmaceutical market 4 major trends.

    Favorites . . . In the second half of the pharmaceutical market 4 major trends.

    • Last Update: 2020-07-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Special Writer/Atropinedeparture in the second half of 2020the pharmaceutical industry has always been a policy market, in the first half of 2020, the hospital terminal market in the gradual recovery, some places have appeared retaliatory consumption, but the overall sales side of the data under pressureOn the other hand, the technical requirements of the research and development side are constantly increasingpolicy intensive introduction so that the second half of 2020 will become a number of policy implementation start-up periodSo under the influence of policy, what is the trend of pharmaceutical market development?'s main policy and its impact:1) Third batch of generic consistent evaluation tape procurement: mainly affecting the recent adoption of consistency evaluation of generic drugs2) 2020 health insurance negotiations: mainly affect ingested on recently approved new drugs and 2018 into the health insurance negotiations catalog products3) provincial belt procurement: mainly affectthe disapproved of the provinces sales ranking products4) Pay by disease
    If the renewal rate of the 2019 health insurance negotiation products, 27 of the 31 renewal drugs were successful, at 87%, with an average price reduction of 26.4%A total of 17 anti-cancer drugs are included in the 2018 health care negotiations, with about 15 expected to be successfulOf the 119 new breeds in 2019, 70 negotiations were successful, and 49 products that have not been successfully negotiated are likely to return to the negotiating tableof which PD-1/PD-L1 drugs will not be a single PK worthy of attention, in addition to entering the health insurance of the Sindili monotag, later listed with the classic Hodgkin lymphoma indicationofs of Carelli zuma and terelli bead singtagCompetitions for non-small cell lung cancer include Paboli-zhumonodatin, Navuliu monotophosis and difalyu-yu-singtagPD-1 Each product has a billion-dollar annual sales, and there are corresponding drug-giving opportunities, and it remains to be seen whether health insurance can be successfully negotiated -belt procurement before the purchase volume and the actual volume of a certain gap, with the many training, and the introduction of last year's procurement volume to maintain a certain increase, the number of medical institutions around the report is also more and more close to the actual procurement volume, which also means that manufacturers estimate profits are also more and more clear The number of biosimilar drugs and original research manufacturers is not more than 3, this tape procurement does not participate, but does not exclude next year will enter the national belt procurement list the medical institutions use the winning productcorresponding incentive punishment policy, medical institutions will be inclined to use the winning products This will further force companies to bid lower prices, and the price war is likely to intensify impurities are no longer included in the scope of thinking of the purchased products, sandatin and metformin into the procurement catalog It is not clear what will be handled if the winning manufacturer finds that it is not up to standard the number of belt procurement at the national level is limited after all, even if this time a total of 86 rules into the band procurement, in fact three batches down, into the volume of procurement products are after all a few, the national commonly used tender product regulations nearly 20,000, relying on the national through the consistency evaluation of the band procurement in the short term can not solve the current clinical needs, the provinces still need dynamic bidding, so the need to focus on the provincial band procurement model pilot, very likely to become the national procurement of sample At present, upgrade tape procurement is mainly to antibiotics, digestive system proton pump inhibitors, key monitoring products, water needles and other products that have not passed the consistency evaluation but sales ranking Some products that do not require consistency evaluation are likely to be on a mandatory list of provincial tenders, such as large water needles for determining the efficacy of ingredients the main impact of pay-per-disease is the cost of packing the entire process before and after surgery The cost of drugs inevitably becomes cost, which means that doctors will choose cost-effective drugs, but the safety and effectiveness of the drug must be online, otherwise the results of the doctor's surgery can not be consolidated, but also will be abandoned by the market in the big environment is the main theme of price reduction, how to improve operational efficiency will be a necessary lesson for pharmaceutical companies 's main policies and their impact: 1) "Drug Registration Management Measures": favorable innovative drugs and Chinese medicine research and development, generic drug research and development more standardized 2) injection consistency evaluation: injection agent band procurement is coming 3) raw material association review: data incomplete CDE does not accept declaration
    current chemical drugs, Chinese medicine and biological products related to the registration of supporting documents have not been officially released, is expected to affect the domestic registration of drugs new drugs and domestic unlisted foreign imported drugs are the recent drug registration declaration of more categories of products, the recognition of the import of drugs overseas clinical data policy is to speed up the listing of imported drugs, the accelerated listing of imported drugs will still be in the third phase of clinical similar indications of the domestic new drug competition impact, to PD-1 as an example, even if the domestic drug to take conditional listing, but the import of new drugs marketed before the first domestic PD-1 market whether it is the raw material stylistic drug can not be commissioned production, or generic raw materials can be directly research and development declaration, it means that API manufacturers in the entire generic drug production supply chain occupies a very important link It has become a popular way for the preparation manufacturers to own or control raw materials pharmaceutical plants In the short term, enterprises with the integration of API-preparations are more likely to counter policy risks the clinical value of the chemical injection generic sinnuse, which is not able to determine the reference formulation, does not require consistency evaluation, such as sodium chloride injection, glucose injection, sodium glucose injection, injection water, etc Due to the large clinical use of the above-mentioned products, the market size of the product market is often in the forefront of the sales market, such as sodium chloride national market close to 18 billion yuan, glucose national market close to 8 billion yuan It is expected that the above-mentioned products will be purchased in the provinces or in tape the initiation of the injection consistency evaluation means a shuffle of injection manufacturers In addition to the possibility that threshold-based products such as special formulations may be less competitive than competitive pressures, products that used to enjoy separate pricing treatment for ordinary injectables may face both price and performance the research and development pressure of ordinary injections mainly comes from the pharmaceutical part, in terms of production costs, injections are more dependent on API, and enterprises with integrated raw material-preparation are more likely to win the competition products that have been approved for consistency evaluation of listed injections will also be available for the second half of the year as soon as possible At present, the products that can be approved by injection are still approved according to the newly registered classification registration declaration (depending on the consistency evaluation), it is expected that the first batch of injection consistency evaluation through the products will also be the fourth batch of belt procurement catalog can be launched generics may need to be concerned that it is becoming harder to challenge patents as patents become more internationally linked Genericdrugs can refer to the clinical data of foreign listed original research, the new 3 categories of registration declaration is expected to increase However, with the deepening of international intellectual property cooperation, the difficulty of domestic generic supsopharmaceuticals to challenge patents may become more difficult Unless there is a shortage of market-driven clinical drug use for major and rare diseases, special populations, etc., and has entered the list of drugs that encourage generic sis Chinese medicine has recently become a new research and development focus, the merger and acquisition of Chinese medicine began to frequently, especially the ancient side, medical institutions in-house preparations, manufacturers but in fact not in the production of products will be the target 's main policies and their impact: 1) "Measures for the Supervision and Administration of Drug Production" 2) 2020 edition of the China Pharmacopoeia 3) "Listed Drug Change Stakes and Reporting Information Requirements (Draft for Comments)" MAH national implementation has become a general trend, regardless of the whole life cycle management or MAH's entire management system is related to quality changes to drug licensing holders require a compliant quality system before and after docking and consistent quality drugs have become the responsibility of drug licensing holders, whose responsibilities are mainly in the monitoring of adverse reactions from the past drug traceability system to promote the discovery, the terminal is not willing to cooperate, if the drug traceability system to the enterprise self-report, that unified code how to prepare and run in a system will be difficult, when the channel side ignored the needs of drug licensing holders, drug licensing holders of the traceability system control is low, medical institutions will be the key data of the traceability system, and most likely as the real world data with the advance of MAH system, the change of drug market license holders, the new drug production enterprises to become entrusted processing enterprises to increase the number of supplementary applications, the national production resources may be with the implementation of MAH system in the short-term But overall, overcapacity production lines could face being phased out the main policies and their effects: 1) Medical representative record management measures
    2) to carry out outpatient expenses cross-provincial direct settlement pilot 3) Internet and medical medical representative filing method once again issued a draft for comments, once again reiterated that the pharmaceutical representative may not undertake the task of drug sales, collection and processing of purchase and sale bills, without the record shall not participate in the medical institutions to carry out academic promotion activities, not to participate in the number of pharmaceutical prescriptions issued by doctors and pharmaceutical companies to be required to undertake the necessary drug marketing It is prohibited for drug market licensing holders, drug manufacturers, drug-operating enterprises and medical institutions to give or receive kickbacks or other improper benefits in the purchase and sale of pharmaceuticals With the establishment of the blacklist mechanism and the hook-up band procurement, the industry's return to academia is the general trend compliance, prices are down, pharmaceutical marketing needs to find new opportunities to break through outpatient mutual assistance guarantee mechanism has been launched, fully implement the high blood pressure, diabetes outpatient drug guarantee mechanism, standardize the simplification of outpatient strifyding disease protection identification process, it is expected that this process is determined before the cross-provincial settlement The direct settlement of outpatient fees across provinces means that patients can choose to buy drugs from the provinces that have expired the original research drug Internet diagnosis and treatment work may be gradually liberalized For pharmaceutical companies, the supply chain's Internet-plus reform is also a concern, as a way to get drugs to reach patients faster and reduce exposure after Internet-medica Commercial companies are expected to be deeply involved in the reform of post-Internet drug delivery, and well-channeled commercial companies in pharmacies and medical clinics are more likely to win new growth.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.